Larvol Delta - Aston-Sci-Receives-IND-Approval-from-FDA-for-Phase-2-Clinical-Trial-of-Therapeutic-Cancer-Vaccine-AST301-in-Patients-with-TNBC

AST-301 - University of Washington, Aston Sci., EpiThany

https://www.prnewswire.com/news-releases/aston-sci-receives-ind-approval-from-fda-for-phase-2-clinical-trial-of-therapeutic-cancer-vaccine-ast-301-in-patients-with-tnbc-301616322.html

Sep 1, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next